Introduction {#Sec1}
============

Approximately half of all cutaneous melanomas display somatic mutations in the BRAF gene and in 90% of those the mutation is a single amino acid substitution from valine to glutamic acid at codon 600 in exon 15 (BRAF V600E) \[[@CR1]\]. The mutated enzyme activates the mitogen-activated protein kinases (MAPK) pathway leading to cell proliferation \[[@CR2]\].

Dabrafenib (GSK2118436), registered as Tafinlar®, is an inhibitor of BRAF V600E approved for treatment of non-resectable stage III or stage IV metastatic melanoma carrying the mutation. In a phase III trial, 53% of patients experienced adverse events of grade 2 or greater including squamous cell carcinoma (SCC), pyrexia, fatigue, headache, arthralgia, and different cutaneous adverse drug reactions \[[@CR3]\]. In order to limit the effects of these adverse drug reactions through individualized dosing of dabrafenib, it is important to study the pharmacokinetics of the drug.

After oral absorption dabrafenib is converted into hydroxy-dabrafenib mainly by cytochrome P450 2C8 (CYP2C8) and CYP3A4. Hydroxy-dabrafenib is further metabolized into carboxy-dabrafenib by CYP3A4, which is non-enzymatically converted into desmethyl-dabrafenib \[[@CR4], [@CR5]\]. Together, these metabolites constituted 76% of the circulating radioactivity in humans after administration of 14C-labeled dabrafenib. Minor metabolites include a glucuronide of hydroxyl-dabrafenib and further oxidations of desmethyl-dabrafenib \[[@CR4]\]. The pharmacokinetics of dabrafenib exhibits a great deal of inter-patient variability. A 73% inter-patient coefficient of variation (CV) in maximum concentration at steady state was observed \[[@CR6]\]. The metabolism of dabrafenib is rapid with a half-life of 4.8 h \[[@CR7]\]. Even though dabrafenib is given twice daily, Falchook et al. \[[@CR8]\] showed that the plasma concentration of dabrafenib and hydroxy-dabrafenib vary 16- and 7-fold, respectively, during a 12-h period after a 150-mg dose of dabrafenib at steady state (day 15). However, the concentrations of carboxy-dabrafenib and desmethyl-dabrafenib were more stable (around 1.5-fold variability).

Predictions of clinical effect and toxicity is further complicated by the fact that hydroxyl-dabrafenib and desmethyl-dabrafenib show activity on BRAFV600E with IC50 values approximately 3- and 2-fold higher than dabrafenib, respectively \[[@CR9]\]. Given observed plasma levels, it is likely that these metabolites contribute significantly to the clinical effect and/or toxicity. It is therefore of importance to evaluate the impact of inter-patient variability in metabolite plasma levels on clinical efficacy and risk of adverse events and thus a need for analytical methods providing information on the plasma levels of dabrafenib metabolites.

Two methods to measure dabrafenib in plasma have previously been described \[[@CR4], [@CR10]\]. The method by Sparidans et al. \[[@CR10]\] used protein precipitation followed by dilution coupled to reversed-phase liquid chromatography-tandem mass spectrometry (LC-MS/MS) to analyze dabrafenib in mouse plasma using an analogue of vemurafenib, PLX4720, as the internal standard. The method does not detect any metabolites and was not designed for human plasma. The method by Bershas et al. \[[@CR4]\] used two separate liquid-liquid extractions to analyze dabrafenib and three metabolites (hydroxyl-, carboxy-, and desmethyl-dabrafenib) in human plasma. The method used isotopically labeled internal standards for all analytes. Although the method allows the possibility of measuring dabrafenib metabolites in plasma the two separate sample preparations are impractical and the lack of commercially available metabolite reference standards makes it expensive to implement in the laboratory.

A more cost-efficient approach successfully used previously by us (research groups of Vikingsson and Gréen) for BRAF inhibitor vemurafenib \[[@CR11]\] and EGFR-inhibitor erlotinib \[[@CR12]\] is to use human liver microsomes (HLMs) and patient samples to identify metabolites and use the parent drug as the calibrator.

The aim of this study was to develop and validate a simple and affordable LC-MS/MS method to measure dabrafenib and all major metabolites for potential use in clinical trials.

Material and methods {#Sec2}
====================

Chemicals and reagents {#Sec3}
----------------------

Dabrafenib (purity \>99%) was obtained from Selleck Chemicals (Munich, Germany). Internal standard Erlotinib-d6 was acquired from Toronto Research Chemicals Inc. (North York, ON, Canada). Ammonium acetate and dimethyl sulfoxide (DMSO) of analytical grade or higher were obtained from Sigma Aldrich Sweden AB (Solna, Sweden). Acetonitrile hypergrade for LC-MS LiChrosolv from VWR (Stockholm, Sweden). Purified water was prepared in the laboratory using a Milli-Q Gradient purchased from Millipore AB (Solna, Sweden).

Seven blood samples were obtained between 14 and 17 h after last dose from four different patients with disseminated melanoma after 1, 2, or 3 months of treatment with dabrafenib at the full recommended dose of 150 mg BID orally. After 1 month, patients are expected to have reached steady-state levels of dabrafenib and metabolites (the half-life of dabrafenib and metabolites was reported to be 4.8 h and less than 21 h, respectively \[[@CR7]\]). Plasma was collected after centrifugation, immediately frozen, and stored at −80 °C until analysis. The study protocol was approved by the Ethical Review Board in Stockholm (DNR 2011/1980-31/1) and written informed consent was obtained from patients prior to study entry. Drug-free ethylenediaminetetraacetic acid (EDTA) plasma was donated from six volunteers (three males and three females) with an average age of 26 (22--30) years.

Human liver microsomes (pool of 200 donors), NADPH regenerating system solution A (26 nM NADP+, 66 mM glucose-6-phosphate, and 66 mM MgCl~2~), NADPH regenerating system solution B (40 U/mL glucose-6-phosphate dehydrogenase), UGT reaction mixture solution A (25 mM uridine-5′-diphospho-glucoronic acid (UGDPA)), and UGT mixture solution B (250 mM Tris-HCl, 40 mM MgCl~2~, and 0.125 mg/mL alamethicin, pH 7.5) were purchased from BD Bioscience (Stockholm, Sweden).

Chromatographic conditions {#Sec4}
--------------------------

The chromatographic separation was performed using an Acquity ultraperformance liquid chromatography (UPLC) system consisting of column manager, sample manager, and binary solvent manager, all from Waters (Sollentuna, Sweden). Three microliters of sample was separated on an Acquity UPLC BEH C18 column (100 × 2.1 mm, 1.7 μm) with a BEH VanGuard C18 guard Column (5 × 2.1 mm, 1.7 μm) maintained at 55 °C. Five millimolars ammonium acetate and acetonitrile was used as mobile phases with a flow rate pf 0.65 mL/min. The analytes were eluted with a linear gradient from 20 to 45% acetonitrile for the first 6 min (0--6 min), before returning to initial conditions of 20% acetonitrile to re-equilibrate the last minute (6--7 min). Due to the short equilibration time, the first two injections of a sequence should be ignored.

MS/MS detection was performed using a Xevo TQ triple quadrupole mass spectrometer operated in positive electrospray ionization (ESI) mode, also from Waters. The source temperature was 150 °C, desolvation temperature 600 °C, cone gas flow 24 L/h, desolvation gas flow 1000 L/h, and collision gas flow 0.14 mL/min (argon). The analytes were monitored in multireaction monitoring mode (MRM). Specific parameters are given in Table [1](#Tab1){ref-type="table"}.Table 1Details of mass spectrometric detectionCompoundRetention time (min)Measurement window (min)Precursor ion (*m*/*z*)Cone voltage (V)Product ion (*m*/*z*)Collision energy (eV)Dwell time (ms)Dabrafenib6.015.7--7.0520.148307.23635277.07035Erlotinib-d64.623.7--5.7400.244287.23035339.22235Carboxy-Dab1.321.2--1.9550.135329.13535314.25535Gluc met (novel)2.182.1--2.5696.140291.17321328.36021M262.822.1--3.2522.247309.14021291.14621Hydroxy-Dab3.363.2--3.7536.250293.14875323.13975Desmethyl-Dab4.844.4--5.0506.246293.24035309.13735M315.195.0--5.7504.140291.14335307.13235*Dab* dabrafenib, *Gluc met* glucuronidated metabolite

Sample preparation {#Sec5}
------------------

Fifty microliters aliquots of plasma was thawed and precipitated with 200 μL of internal standard mixture containing erlotinib-d6 (200 ng/mL) in acetonitrile. Following vortex mixing, the samples were centrifuged (17530 RCF, 5 min, 4 °C). The supernatant (150 μL) was mixed with 150 μL water and transferred to a 0.7-mL 96-well plate.

Stock solutions, calibration, and controls {#Sec6}
------------------------------------------

Dabrafenib was dissolved in DMSO to a concentration of 1 mg/mL. Internal standard erlotinib-d6 was dissolved in DMSO to a concentration of 1.9 mg/mL. Calibration and quality control (QC) working stock solutions were prepared from the stock solutions by dilution in an acetonitrile/water (50:50, *v*/*v*) mixture.

Calibration standards for dabrafenib were prepared at seven levels in the concentration range 5--5000 ng/mL (5-15-60-250-1000-3750-5000) by diluting the corresponding working stock solutions 1:10 with drug-free plasma. The upper limit of quantification (ULOQ) was selected based on the highest expected dabrafenib concentration, and the lower limit of quantification (LLOQ) was selected based on observed carry-over from the ULOQ. LOD was not determined as LLOQ was limited by the carry-over. QC samples were prepared separately from the calibration standards at four levels (LLOQ-low-medium-high, 5-15-250-3750 ng/ml).

Due to the lack of reference materials, the six metabolites were semi-quantitatively determined using the calibration curve for dabrafenib. The bias caused by, among other things, differences in recovery and ionization efficiency was not corrected for. This bias is indicated by the addition of an asterisk to the units of metabolite concentrations.

Human liver microsome incubations {#Sec7}
---------------------------------

Dabrafenib was incubated at 10 μM for 120 min. For an incubation volume of 1 mL, 50 μL NADPH regenerating system solution A, 10 μL NADPH regenerating system solution B, 200 μL UGT mixture solution A, 80 μL UGT mixture solution B, and 25 μL HLM (0.5 mg protein) were diluted to 995 μL in water and preheated to 37 °C in a water bath. The reaction was started by addition of 5 μL dabrafenib stock solution (5 mM in DMSO) and terminated by addition of 150 μL of incubate to four volumes of ice-cold acetonitrile. After centrifugation, the supernatant was evaporated under nitrogen and reconstituted in mobile phase. A negative control without dabrafenib was used as well as a degradation control without HLM.

Metabolite identification {#Sec8}
-------------------------

Metabolites previously reported by Bershas et al. \[[@CR4]\] were primarily identified after incubations with HLM. Single ion monitoring (SIM) was used to identify the molecular ion and multireaction monitoring (MRM) transitions were established based on those reported by Bershas et al. \[[@CR4]\]. The naming convention presented by Bershas et al. \[[@CR4]\] was maintained. The MRM transitions were optimized in a stepwise fashion with regard to Q1 and Q3 mass, cone voltage, and collision energy using intra-run comparisons of different settings. Only metabolites identified in patient plasma were included in the final method. For the optimized transitions, see Table [1](#Tab1){ref-type="table"}.

Previously unknown metabolites were identified by full scan of the HLM extract in the 200--800 *m*/*z* range (segmented over several runs to increase sensitivity). To be considered a metabolite of interest it had to be present in patient plasma but not in HLM-negative control nor blank plasma. The structures of unknown metabolites were assigned based on obtained product ion spectra, which was also the basis for MRM transitions. MRM transitions were further optimized as detailed above for previously reported metabolites.

Method validation {#Sec9}
-----------------

For dabrafenib the method was validated according to international guidelines from the Food and Drug Administration (FDA) \[[@CR13]\] and the European Medicines Agency (EMA) \[[@CR14]\] for bioanalytical methods.

The validity of the quadratic calibration model (weighted 1/*x* ^2^) was established by back-calculating concentrations for calibration standards from six independent runs. Carry-over was evaluated by analyzing drug-free plasma after the highest calibration standard (*n* = 3). Intra-batch (*n* = 6) and inter-batch (*n* = 6) accuracy and precision were determined at all four QC levels. Selectivity was determined by analysis of drug-free plasma obtained from six individuals.

The matrix factor at low and high QC levels were evaluated in six individuals and determined as the area ratio of dabrafenib between spiked drug-free plasma from six individuals and dabrafenib spiked in 40% acetonitrile (*n* = 3). The factor was normalized by the corresponding internal standard matrix factor \[[@CR13], [@CR14]\].

Recovery at QC low and QC high was evaluated by spiking drug-free plasma from six individuals and determined as the area ratio between a sample spiked before extraction and a sample spiked after extraction adjusted for internal standard recovery.

Stability was evaluated at the low and high QC levels. Processed sample stability by re-injection of calibration and QC samples after 24 h at 5 °C. Freeze-thaw stability (*n* = 3) was determined for three freeze-thaw cycles at −80 °C. Short-term stability of dabrafenib was investigated in whole blood and plasma using spiked drug-free plasma (*n* = 2) stored at room temperature or 5 °C for 0, 24, 48, and 72 h, respectively. Long-term stability of dabrafenib (QC low, QC middle, and QC high; *n* = 3) was determined for a sample stored at −80 °C for 16 months. Accuracy within ±15% of the nominal value was required to consider dabrafenib stable under all conditions.

As no reference standards were available, a full validation of the metabolite measurements was not possible. Instead, the specificity was validated analyzing blank samples (*n* = 6) and the repeatability was determined by duplicate analysis (inter-day) of patient samples (*n* = 7). The latter is not supported by the validation guidelines used \[[@CR13], [@CR14]\].

Results {#Sec10}
=======

In this project, a method was developed to measure dabrafenib and six metabolites, including a glucuronidated metabolite previously not described. Names of metabolites, including M26 and M31, were selected to correspond to those used by Bershas et al. \[[@CR4]\]. Possible structures are given in Fig. [1](#Fig1){ref-type="fig"}. The novel glucuronidated metabolite is suggested to be the conjugate of metabolite M31 based on the mass of the molecule, the fragment 291 also observed in M31, and the fact that the isopropyl moiety seems to be a prevalent site of hydroxylation. However, several other structures are possible.Fig. 1Structure suggestions for identified metabolites. The *asterisk* denotes that several other structures are possible

Representative chromatograms of dabrafenib at LLOQ are shown in Fig. [2](#Fig2){ref-type="fig"}. Chromatograms of the metabolites are shown in Fig. [3](#Fig3){ref-type="fig"} and estimated concentration ranges for each metabolite (based on dabrafenib calibration) are found in Table [3](#Tab3){ref-type="table"}.Fig. 2Chromatograms of dabrafenib in lowest patient sample (*A*, 75 ng/mL) and at LLOQ (*B*, 5 ng/mL) compared to blank (*C*) and the internal standard D6-erlotinib (*D*) Fig. 3Typical chromatogram of patient sample. Carboxy-dabrafenib 400 ng/mL\*, glucuronidated metabolite 32 ng/mL\*, M26 230 ng/mL\*, hydroxyl-dabrafenib 280 ng/mL\*, desmethyl-dabrafenib 660 ng/mL\*, M31 550 ng/mL\*, and dabrafenib 1400 ng/mL. \*Semi-quantification based on the calibration curve of dabrafenib

Structure assignment of novel metabolite {#Sec11}
----------------------------------------

The novel glucuronide metabolite was identified based on the presence of peaks *m*/*z* 291 and *m*/*z* 328 in the product ion spectra, see Electronic Supplementary Material (ESM) Fig. [S1](#MOESM1){ref-type="media"}. Even though the mechanism of formation is unclear, the fragment *m*/*z* 291 was reported by Bershas et al. \[[@CR4]\] for metabolites M26 and M31, both of which are modified solely at the isobutyl group. This is also to some extent supported by *m*/*z* 328, formed by the loss of the glucuronide and the difluorobenzenesulfonamide moiety.

Method validation {#Sec12}
-----------------

The calibration model was valid with as the average back-calculated concentrations were 97--103% for all calibration standards (see ESM Table [S1](#MOESM1){ref-type="media"}).

The carry-over was on average 0.02% (corresponding to 14% of LLOQ) and 0.06% for dabrafenib and D6-erlotinib, respectively (see ESM Table [S2](#MOESM1){ref-type="media"}).

Intra- and inter-batch accuracy was within 86--95 and 89--91% for all QC levels, respectively. Intra- and inter-batch imprecision (CV) was below 7 and 11% for all QC levels, respectively. Details can be seen in Table [2](#Tab2){ref-type="table"}. An accuracy of 86% and a precision of 7% validated the suitability of the selected LLOQ.Table 2Accuracy and precisionIntra-batch (*n* = 6)Inter-batch (*n* = 6)QC levelAccuracy (%)Precision (%)Accuracy (%)Precision (%)LLOQ^a^867899Low887918Medium9539111High922918^a^ *n* = 5

No interfering peaks for dabrafenib or any of the metabolites were identified in blank plasma (*n* = 6). A matrix factor of 2.06 and 1.28 was observed at low and high QC levels. It was stable with a CV of no more than 2% between different sources of plasma (*n* = 6) (see ESM Table [S3](#MOESM1){ref-type="media"}). Recovery at low and high QC levels for dabrafenib and the internal standard was between 104 and 115%; IS-corrected recovery for dabrafenib was 110 and 96% at the low and high QC levels, respectively (see ESM Table [S4](#MOESM1){ref-type="media"}).

Processed samples were stable for 24 h at 5 °C. Dabrafenib spiked in whole blood or plasma was stable for 72 h at room temperature and at 5 °C. In the plasma, dabrafenib was also stable for three freeze-thaw cycles and during 16 months of storage at −80 °C (see ESM Table [S5](#MOESM1){ref-type="media"}).

Discussion {#Sec13}
==========

The presented method was not developed as a TDM method, but to meet the need of our clinical studies, a method capable of correlating patient plasma levels with clinical outcomes such as efficacy and adverse events. As some metabolites have been shown to be active \[[@CR9]\], it was important to include as many of the metabolites as possible. However, a method similar to that presented by Bershas et al. \[[@CR4]\] requires substantial resources, which were not available.

A more cost-efficient approach was therefore selected in which the metabolites were semi-quantified using the dabrafenib calibration curve eliminating the need for custom synthesis reference materials. It did however introduce a bias that is unknown and potentially substantial. That said, the bias should be similar in all samples meaning that even though the true concentrations of the metabolites cannot be determined with any accuracy, the concentration in a given sample relative to other samples can. Hence, metabolite plasma levels can be correlated to i.e. adverse events. Should the plasma levels of any given metabolite correlate strongly with a particular adverse event that metabolite could be synthesized and easily added to the method. As the patient samples appear to be stable at −80 °C re-analysis providing accurate concentrations would then be possible.

As sensitivity was not a major issue and a blood sample provides more plasma than needed, the main concern when developing the method was to make the sample preparation cost-efficient. Protein precipitation was an obvious choice as it is rapid and requires a minimum of consumables. Protein precipitation was also used by Sparidans et al. \[[@CR10]\] but that method was limited to dabrafenib and did not include any metabolites.

Given recent developments in treatment practice, dabrafenib is frequently administered together with trametinib. Although not included in the presented method, it has been shown that trametinib can be analyzed together with dabrafenib on a C18 column using ammonium acetate-based mobile phases \[[@CR15], [@CR16]\]. This indicates that trametinib and possible trametinib metabolites probably could be included into the presented method using a modified gradient.

In the method, six metabolites were included as seen in Table [1](#Tab1){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}. Five of them were previously reported by Bershas et al. \[[@CR4]\], which came as no surprise given the thoroughness of that excellent study. For these metabolites, the identity was ensured by verifying the presence of the four or five characteristic fragment ions provided by Bershas et al. \[[@CR4]\]. For the novel metabolite, the identity was inferred by examining the product ion spectra (ESM Fig. [S1](#MOESM1){ref-type="media"}) and even though the information was limited, the fragments identified the metabolite as a hydroxyl glucuronide of M31.

The described method was successfully validated with regard to dabrafenib. It comprises of a simple protein precipitation allowing all metabolites to be included in the same sample preparation. A substantial matrix factor was observed for dabrafenib but as this factor was highly reproducible between different matrices and as the calibration standards are prepared in the plasma, it will not significantly affect the precision or the accuracy of the method.

In general, the bias of the metabolite concentrations appeared to be reasonably small. Falchook et al. \[[@CR8]\] reported similar metabolite concentrations as seen in Table [3](#Tab3){ref-type="table"} with the exception of carboxy-dabrafenib where they reported an 8-fold higher concentration than found in this study. As carboxy-dabrafenib is a carboxylic acid and the chromatography is run at neutral pH, it is likely to mainly be present as negative ions, which are hard to ionize in positive ESI mode. Thus, carboxy-dabrafenib is expected to ionize poorly in the presented method compared to dabrafenib, which was used for quantification, providing a plausible explanation for the differences in observed concentrations compared to Falchook et al. \[[@CR8]\].Table 3Plasma concentrationsCompoundMedian C (ng/ml)RangeDiffDabrafenib400(75--1400)19-foldCarboxy-Dab450^a^(230--690)3-foldGluc met38^a^(22--65)^b^3-foldM26120^a^(59--230)4-foldHydroxy-Dab74^a^(19--278)15-foldDesmethyl-Dab400^a^(170--660)4-foldM31400^a^(160--590)4-fold*C* plasma concentration, *Dab* dabrafenib, *Diff* difference between the highest and lowest concentrations, *Gluc met* glucuronidated metabolite^a^Semi-quantification based on the calibration curve of dabrafenib^b^ *N* = 6 due to technical reasons

That said, the method is suitable to compare metabolite levels between patients in the ongoing clinical studies and identify metabolites correlated to treatment efficacy, adverse events, or genetic variability. If any such metabolites are identified, they can be synthesized and validated without changing the methodology used.

Steady-state levels of dabrafenib and metabolites showed considerable inter-patient variability although all patients were receiving the full-prescribed dose of dabrafenib (Table [3](#Tab3){ref-type="table"}). This was in line with earlier observations by Suttle et al. \[[@CR6]\] (73% CV in maximum concentration at steady state) and indicates that the inter-patient variability of dabrafenib is even higher than observed for vemurafenib (30--60%) 1\[[@CR17]\].

Also, contrary to vemurafenib \[[@CR11]\], a substantial amount of metabolites are present in the plasma at steady state, as can be seen in Fig. [3](#Fig3){ref-type="fig"}. A significant inter-patient variability in metabolite plasma levels was observed, especially for hydroxy-dabrafenib as seen in Table [3](#Tab3){ref-type="table"}.

Substantial inter-patient variability in dabrafenib pharmacokinetics indicates a risk of highly variable plasma levels of dabrafenib and metabolites on standardized therapy. High plasma levels could possibly explain some of the observed adverse effects such as pyrexia and squamous cell carcinoma. On the other, low plasma levels could possibly induce resistance, as shown for other agents in vitro \[[@CR18]\]. Together, these findings warrant further research into therapeutic drug monitoring and the importance of inter-patient pharmacokinetic variability of dabrafenib and its metabolites.

Conclusions {#Sec14}
===========

In conclusion, a method capable of measuring dabrafenib and six metabolites is presented. The method is simpler and more cost-effective than previously published methods to measure metabolites. The method was fully validated with regard to dabrafenib and well suited for clinical studies.
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